TB-500 + BPC-157
Publiceret forskning og dokumentationsgrundlag
One published study has directly tested BPC-157 and TB-500 together against each agent alone, and it found no additive benefit. Beyond that single rat Achilles tendon experiment and one retrospective human chart review in which some knee-pain patients received BPC 157 combined with thymosin beta-4, there is no peer-reviewed evidence for the combination. All other support is component-level: the two peptides have separate preclinical literatures that have been reviewed together in sports-medicine journals, but no synergy has been demonstrated in any model.
- BPC-157 og TB-500 er to peptider gennemgået sammen i idrætsmedicinske tidsskrifter.
- Et rotterforsøg fandt ingen ekstra fordel ved at kombinere de to ved seneskade.
- Intet menneskeligt forsøg har testet kombinationen, og ingen synergi er påvist.
9 studier · 6 siden 2023 · nyeste 2026
- Undersøgelser citeret
- 9
- Publiceret 2023+
- 6
- Nyeste artikel
- 2026
- Sidst gennemgået
- okt. 2026
Tilbagevendende temaer i litteraturen
- combination versus monotherapy tendon healing
- convergence on shared downstream repair pathways
- absence of demonstrated synergy
- sports medicine gray-market peptide stacking
9 offentliggjorte studier.
Sorteret efter styrken i studiedesignet og derefter efter nyhed. Hver post linker til sin kildepost, så fundet kan kontrolleres mod artiklen i stedet for at tages på vores ord.
- 01Systematisk gennemgang2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, et al. · Am J Sports Med · PRISMA-guided scoping review of six peptides including BPC-157 and TB-500 against musculoskeletal tissue outcomes
Sixty-seven percent of the identified literature used preclinical animal models and human clinical studies were limited to a handful of investigations. The review reported each compound separately and identified no combination trials.
- 02Systematisk gennemgang2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, et al. · HSS J · systematic review of the BPC-157 musculoskeletal literature
The review synthesised preclinical evidence for fracture, tendon, ligament and muscle healing and recorded the compound's lack of FDA approval and its prohibited status in professional sport. No combination studies were included.
- 03Humant klinisk2021
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee E, Padgett B · Altern Ther Health Med · retrospective chart review at a single private clinic, 2019-2020; 17 patients given intra-articular BPC 157 alone or combined with thymosin beta-4, telephone follow-up in 16
The review recorded self-rated pain change after intra-articular injection of BPC 157 alone or with thymosin beta-4. It used no validated outcome instruments and no control group, and did not separate combination recipients from monotherapy recipients in a way that permits inference about combination effect. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).
- 04Dyr in vivo2026
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
Biçer O, et al. · Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats in 4 groups of 8 including a dedicated BPC-157 + TB-500 combination arm; intraperitoneal dosing for 4 weeks
This is the only published study to test the combination against each peptide alone. The combination group showed significantly lower total Movin scores than controls, but the authors stated explicitly that combined treatment did not confer additional benefit compared with either agent alone, and hypothesised convergence on shared downstream pathways.
- 05Dyr in vivo2021
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
Japjec M, et al. · Biomedicines · rat myotendinous junction defect created by dissecting the quadriceps tendon from the quadriceps muscle
BPC 157 improved macroscopic, microscopic, biomechanical and functional outcomes at the myotendinous junction, with associated changes in eNOS and COX-2 mRNA and in nitric oxide levels. Component-level evidence only.
- 06Dyr in vivo1999
Thymosin beta4 accelerates wound healing
Malinda KM, et al. · J Invest Dermatol · rat full-thickness dermal wound model; topical or intraperitoneal thymosin beta4
Thymosin beta4 increased re-epithelialisation by 42 percent at 4 days and up to 61 percent at 7 days versus saline controls, with increased collagen deposition and angiogenesis. Component-level evidence only.
- 07Gennemgang2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, et al. · Am J Sports Med · narrative review of injectable peptide therapies including BPC-157, TB-4 and TB-500
The review found BPC-157 showed potential in tendon and muscle repair that is largely unvalidated in human trials, noted the single human knee case series and its methodological limitations, and stated that TB-4 and TB-500 promoted angiogenesis and tissue repair in preclinical models while human orthopaedic data are lacking.
- 08Gennemgang2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, et al. · Sports Med · narrative review of approved and unapproved peptides marketed direct to patients, covering both BPC-157 and Tb4/TB-500
The review reported favourable animal-model tissue repair outcomes for several unapproved peptides alongside scarce human safety data, and discussed placebo effects and social media amplification as mediators of perceived efficacy. It did not identify combination evidence.
- 09Gennemgang2026
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
Moiz A, et al. · Mo Med · narrative clinical review of unregulated injectable peptides
Named both BPC-157 and TB-500 among unapproved peptides lacking established human safety profiles and described risks of contamination, impurities, inaccurate dosing, pathological angiogenesis and carcinogenesis.
Rapporteret sikkerhedsfund. Authors flagged contamination, impurities and theoretical angiogenesis/carcinogenesis risks for both unregulated peptides.
Hvad denne evidens ikke fastslår.
The single controlled experiment of this combination found no additive benefit over monotherapy, and it was a four-week exploratory rat study with eight animals per group. There is no human trial of the combination, no dose-optimisation work, no long-term follow-up, and no published evidence of pharmacological synergy in any tissue.
Almindelige spørgsmål om forskningen.
- Why are BPC-157 and TB-500 studied together?
The two peptides have separate preclinical literatures that converge on overlapping tissue-repair endpoints, and sports-medicine reviews have appraised them side by side for that reason. That convergence is the stated rationale for pairing them rather than a demonstrated pharmacological interaction. No published work has shown synergy between the two in any model or species.
- Has the BPC-157 and TB-500 combination been tested against each peptide alone?
Once. A 2026 experiment in 32 male Sprague-Dawley rats with Achilles tendon transection and repair compared a control group, BPC-157 at 10 ug/kg/day, TB-500 at 60 ug/kg/day and a dedicated combination arm, with intraperitoneal dosing over four weeks. The combination group showed significantly lower total Movin scores than controls, but the authors stated explicitly that combined treatment did not confer additional benefit over either peptide given alone. The TB-500 group additionally showed a significantly higher maximum load to failure.
- Is there any human evidence for the combination?
There is no human trial of the combination. The only human record is a 2021 retrospective chart review at a single private clinic covering 17 patients who received intra-articular BPC 157 alone or combined with thymosin beta-4, with telephone follow-up in 16. That review used no validated outcome instruments and no control group, and did not separate combination recipients from monotherapy recipients in a way that would allow the combination to be assessed.
Fås i vores katalog
Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning, og intet studie opsummeret her skal læses som en anbefaling.